Mice are valuable for the identification and investigation of genes and mutations that may affect normal cone photoreceptor function, particularly in achromatopsia. There have been nine mouse models of cone photoreceptor function loss (
cpfl) reported since
cpfl1 was first described (Chang B, et al.
IOVS 2001;42:ARVO Abstract 527). The
cpfl retinal phenotype varies across the models and the genetic basis is different for each. Yet, all nine models display the common trait of partial or complete loss of cone function from birth, sometimes with progressive cone cell loss (Chang B, et al.
IOVS 2001;42:ARVO Abstract 527) (Hawes NL, et al.
IOVS 2003;44:ARVO E-Abstract 4531) (Chang B, et al.
IOVS 2006;47:ARVO E-Abstract 2294) (Hawes NL, et al.
IOVS 2004;45:ARVO E-Abstract 3590) (Hawes NL, et al.
IOVS 2006;47:ARVO E-Abstract 4579) (Hawes NL, et al.
IOVS 2007;47:ARVO E-Abstract 1350) (Chang B, et al.
IOVS 2015;ARVO E-Abstract B0250).
4,5 Mouse models also facilitate the development of retinal gene and molecular therapies; two
cpfl models have been central in developing adeno-associated virus (AAV) gene therapies before trials in humans.
6,7 The
cpfl phenotypes model human achromatopsia, a rare (1 in 30,000–80,000), congenital visual condition characterized by diminished or absent cone photoreceptor function.
8 Patients have severely reduced visual acuity (∼20/200), nystagmus, and photophobia.
9 Causative autosomal recessive mutations largely affect genes of the cone phototransduction cascade and are summarized elsewhere.
10